A practical reference on hexenoyl group: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-10 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
== Indications == Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle.
Hospital pharmacists and trained pharmacy technicians compound sterile products for patients including total parenteral nutrition (TPN), and other medications are given intravenously. That is a complex process that requires adequate training of personnel, quality assurance of products, and adequate facilities. Several hospital pharmacies have decided to outsource high-risk preparations and some other compounding functions to companies who specialize in compounding. The high cost of medications and drug-related technology and the potential impact of medications and pharmacy services on patient-care outcomes and patient safety require hospital pharmacies to perform at the highest level possible.
Clytia hemisphaerica is a small hydrozoan-group cnidarian, about 1 cm in diameter, that is found in the Mediterranean Sea and the North-East Atlantic Ocean. Clytia has the free-swimming jellyfish form typical of the Hydrozoa, as well as vegetatively propagating polyps. Clytia hemisphaerica has emerged as a promising model organism as its life cycle, small size, and relatively easy upkeep make it conducive to experimental manipulation and maintenance in a laboratory setting. Some examples of studies already conducted in Clytia include those looking at embryonic development, differential patterns of gene expression during life stages, and wound healing. Clytia's genome was sequenced in full in March 2019.
Ho's extensive research achievements have garnered news coverage in The Economist, Forbes, Nature, CNN, NPR, as well as The Washington Post. He was also featured in the National Geographic Channel program, Known Universe. Most recently, the Augmented AI platform was featured by FuturizeX, a partnership between the X PRIZE Foundation and UCLA. Recent clinical advances using this AI approach to enhance clinical outcomes were recognized among the finalists for the SLAS Innovation Award, selection among the SLAS Technology 10, and featured at the PM3 panel at InnovFest Unbound. Ho currently serves as the Director of The N.1 Institute for Health (N.1), which was previously known as SINAPSE, as well as Director of the Institute for Digital Medicine (WisDM) at the Yong Loo Lin School of Medicine, National University of Singapore. N.1 and WisDM are clinical stage research institutes that harnesses AI and Digital Medicine for novel clinical trial designs for interventional studies. Over ten first-in-human clinical studies based on N.1 and WisDM-developed technologies are ongoing or nearing clearance for the start of prospective clinical studies. N.1 and WisDM have pioneered the development and subsequent clinical translation of platforms pertaining to N-of-1 medicine, digital therapeutics, COVID-19 therapeutic regimen optimization, pain management, cognitive neuroengineering, and novel drug development, among many others. Ho is an elected member of the US National Academy of Inventors (NAI).
In October 2011, a coordinated operation, Operation Linda Nchi between the Somali and Kenyan militaries and multinational forces began against the Al-Shabaab in southern Somalia. By September 2012, Somali, Kenyan, and Raskamboni forces had managed to capture Al-Shabaab's last major stronghold, the southern port of Kismayo. In July 2012, three European Union operations were launched to engage with Somalia: EUTM Somalia, EU Naval Force Somalia Operation Atalanta off the Horn of Africa, and EUCAP Nestor. As part of the official "Roadmap for the End of Transition", a political process that provided clear benchmarks leading toward the formation of permanent democratic institutions in Somalia, the Transitional Federal Government's interim mandate ended on 20 August 2012. The Federal Parliament of Somalia was concurrently inaugurated. The Federal Government of Somalia, the first permanent central government in the country since the start of the civil war, was established in August 2012 with Hassan Sheikh Mohamud elected as president. In August 2014, the Somali government-led Operation Indian Ocean was launched against insurgent-held pockets in the countryside. The next election took place in 2017 with Mohamed Abdullahi Farmajo succeeding as president. Near the end of his presidency, disagreements over the upcoming election prompted Farmajo to sign a controversial 2 year extension that was eventually overturned. In 2022, Hassan Sheikh Mohamud was re-elected for a second term.
Sources: en.wikipedia.org
The coenzyme NAD+ was first discovered by the British biochemists Arthur Harden and William John Young in 1906. They noticed that adding boiled and filtered yeast extract greatly accelerated alcoholic fermentation in unboiled yeast extracts. They called the unidentified factor responsible for this effect a coferment. Through a long and difficult purification from yeast extracts, this heat-stable factor was identified as a nucleotide sugar phosphate by Hans von Euler-Chelpin. In 1936, the German scientist Otto Heinrich Warburg showed the function of the nucleotide coenzyme in hydride transfer and identified the nicotinamide portion as the site of redox reactions. Vitamin precursors of NAD+ were first identified in 1938, when Conrad Elvehjem showed that liver has an "anti-black tongue" activity in the form of nicotinamide. Then, in 1939, he provided the first strong evidence that nicotinic acid is used to synthesize NAD+. In the early 1940s, Arthur Kornberg was the first to detect an enzyme in the biosynthetic pathway. In 1949, the American biochemists Morris Friedkin and Albert L. Lehninger proved that NADH linked metabolic pathways such as the citric acid cycle with the synthesis of ATP in oxidative phosphorylation. In 1958, Jack Preiss and Philip Handler discovered the intermediates and enzymes involved in the biosynthesis of NAD+; salvage synthesis from nicotinic acid is termed the Preiss-Handler pathway. In 2004, Charles Brenner and co-workers uncovered the nicotinamide riboside kinase pathway to NAD+. The non-redox roles of NAD(P) were discovered later.
==== Metabolism ==== Modafinil is metabolized mainly in the liver. It is metabolized mainly via amide hydrolysis into modafinil acid by esterases and/or amidases. In addition, modafinil is metabolized to a lesser extent by sulfoxidation via cytochrome P450 CYP3A4 and CYP3A5 into modafinil sulfone. The drug is also metabolized via aromatic ring hydroxylation and by subsequent conjugation via glucuronidation. The two major circulating metabolites of modafinil are modafinil acid and modafinil sulfone. Both of these metabolites have been described as inactive, and neither appears to contribute to the wakefulness-promoting effects of modafinil. However, modafinil sulfone does appear to possess anticonvulsant effects, a property that it shares with modafinil.
=== 6 March === Sudan filed a case in the International Court of Justice (ICJ) against the United Arab Emirates, accusing it of complicity in genocide by providing weapons to the RSF. Canada imposed sanctions on al-Burhan and Hemedti, citing in part "an unwillingness on the part of the leaders to negotiate an end to the war".
=== Diagnosis === ESR can sometimes be useful in diagnosing diseases, such as multiple myeloma, temporal arteritis, polymyalgia rheumatica, various autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and chronic kidney diseases. In many of these cases, the ESR may exceed 100 mm/hour. It is commonly used for a differential diagnosis for Kawasaki's disease (from Takayasu's arteritis; which would have a markedly elevated ESR) and it may be increased in some chronic infective conditions like tuberculosis and infective endocarditis. It is also elevated in subacute thyroiditis also known as DeQuervain's. In markedly increased ESR of over 100 mm/h, infection is the most common cause (33% of cases in an American study), followed by cancer (17%), kidney disease (17%) and noninfectious inflammatory disorders (14%). Yet, in pneumonia the ESR stays under 100. The usefulness of the ESR in current practice has been questioned by some, as it is a relatively imprecise and non-specific test compared to other available diagnostic tests. Current literature suggests that an ESR should be "obtained on all patients over the age of 50" who have an intense headache.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。